109642-01-5Relevant academic research and scientific papers
1,2-Ethane bis-1-amino-4-benzamidine is active against several brain insult and seizure challenges through anti-NMDA mechanisms targeting the 3H-TCP binding site and antioxidant action
Vamecq, Joseph,Maurois, Pierre,Pages, Nicole,Bac, Pierre,Stables, James P.,Gressens, Pierre,Stanicki, Dimitri,Eynde, Jean Jacques Vanden
experimental part, p. 3101 - 3110 (2010/09/03)
Five bis-benzamidines were screened towards murine magnesium deficiency-dependent audiogenic seizures, unravelling two compounds with efficacious doses 50 (ED50) less than 10 mg/kg. They were also screened against maximal electroshock and subcutaneous pentylenetetrazole- induced seizures, and explored for superoxide -scavenging activity. 1,2-Ethane bis-1-amino-4-benzamidine (EBAB) was selected and evaluated in 6 Hz seizure test (ED50= 49 mg/kg) and at 4 μg/kg in focal cerebral ibotenate poisoning in pups (sizes of both white and grey matter wounds were halved). EBAB was further tested on NMDA-induced seizures in mice (ED50=6 mg/kg) and on 3H-TC -binding to a rodent cerebral preparation (IC50=1.4 μM). Taken as a whole, present data emphasise the suitability of bis-benzamidines as templates for designing brain protective compounds.
Bisbenzamidine derivatives for use as antioxidant
-
, (2009/12/05)
The invention is directed to the use of bisbenzamidine compounds of Formula (I) as antioxidant and as neuroprotective agents, wherein R1, R2, R3, R4 and L have the meaning defined in the claims.
